| Union leader represents more than labor in state
BIRDS LANDING - With a cigar between his lips and a shotgun slung over his shoulder, state labor leader and Contra Costa native Jim Kellogg is the very picture of a man's man. In the testosterone-charged morning, Kellogg joined 90 shooters blasting away at fist-sized clay discs whirring over the grassy landscape in this Central Valley hunting preserve. "After we're done shooting, I'll have a beer and then I'll be a real man," joked Kellogg, a tall and well-built 62-year-old wearing blue jeans and a state Fish and Game T-shirt and cap. The scene, like Kellogg, is deceptively simple. "People have a tendency to underestimate Jim," said longtime friend and Contra Costa Supervisor Mark DeSaulnier. "He doesn't say much and he doesn't have a formal education.
LegalView.com Announces Its New, Free Legal Encyclopedia
LegalView is a new, easy to use, free legal-information resource, for ordinary people seeking information on legal issues and controversies. This new site provides general legal resources such as a legal dictionary and legal encyclopedia, in addition to information about specific legal issues such as mesothelioma and unsafe drugs. Denver, CO (PRWEB via PR Web Direct) July 11, 2006 -- LegalView.com today announces the addition of its new Legal Encyclopedia, based on Cornell University's WEX Encyclopedia. The encyclopedia joins the Legal Dictionary, Legal Directory, and massive legal bookstore as part of a free "everything legal" service bringing legal information and legal resources to ordinary people.
LegalView provides two types of legal information. First, the general legal resources, allowing people to look up legal terms and legal definitions, and to seek legal information through a wide range of legal resources; LegalView's directory includes many thousands of links to useful online resources, for instance, from legal publications and blogs, to lists of expert witnesses and paralegal services.
Asbestos sufferers set to win fair play
The Government moved last night to overturn a House of Lords decision on compensation for asbestos-related deaths. Legal affairs minister Bridget Prentice outlined amendments to the Compensation Bill to reverse the effects of the Barker v Corus judgment in mesothelioma cases. She said: "I recognise that this is an exceptional step - but I believe that it is justified in the exceptional circumstances that apply here." Law lords ruled that workers exposed to asbestos dust by several employers must seek compensation from each. Since 2002, sufferers had been able to seek full compensation without proving which employer had caused the exposure. .
NZ asbestos victims face new setback
The fight to force Australian asbestos manufacturers to compensate thousands of sick and dying New Zealanders who inhaled the killer fibres has suffered a serious knock-back.
This month, the Court of Appeal in Australia overturned a landmark $320,000 payout to former Kiwi Bernard Frost, 61, from company Amaca, a subsidiary of Australian building products giant James Hardie. Frost was exposed to the killer fibres while installing insulation products in Cambridge in 1963-66 but was diagnosed with asbestos-related lung diseases in 2000, four years after he moved to Queensland. Frost's Australian lawyer Graeme Little said he will seek special leave to appeal the decision in the High Court in Australia because it was a case of great public importance.
Cambridge Antibody Technology Announces Acquisition of Oncology ...
CAMBRIDGE, England, July 27 /PRNewswire/ -- Cambridge Antibody Technology (CAT) announces the acquisition of product candidate SS1P (renamed CAT-5001) from Enzon Pharmaceuticals, Inc., based in Bridgewater, New Jersey in May 2006. The safety profile of CAT-5001 has been characterised in two Phase I clinical trials in patients with mesothelioma, ovarian and pancreatic cancer. CAT intends to conduct further pre-clinical studies and to initiate a clinical study in early 2007 exploring dosing of CAT-5001 in combination with cytotoxic chemotherapy. CAT-5001 was discovered and initially developed by the National Cancer Institute (NCI), which is part of the US National Institutes of Health (NIH). The programme was licensed to Enzon and that licence has now been assigned to CAT. Under the original licence agreement with the NIH, CAT will have rights to a portfolio of intellectual property associated with the programmes and will pay future royalties to NIH.
|
